Krystal Alligood

Biography

 Krystal spent fifteen years in the pharmaceutical industry at GlaxoSmithKline.  Her skills in protein analysis, cell-based assays, and immunoassay design contributed to the discovery and development of Tykerb, an FDA approved treatment for metastatic breast cancer.  Krystal’s areas of expertise include development and validation of immunoassays on ELISA, DELFIA, and MSD platforms in a regulated environment.  Her responsibilities include management and execution of PK and biomarker projects supporting preclinical and clinical studies, and preparation of study reports and Standard Operating Procedures.  She has co-authored 18 peer-reviewed publications and several abstracts that have been presented at national and international conferences.  Krystal received a B.S. in biology and chemistry from Campbell University in Buies Creek, North Carolina, and an M.S. in Biochemistry from North Carolina State University.   

Research Interest

 Pharmaceuticals